Expert insights. Personalized for you.
The FDA approved 309 new drugs between 2011 and 2018, 38 per year on average. In 2018, the FDA approved 59 new drugs – an all-time high. The industry loses an average of $40 billion per year on drug development, part of which is due to trial delays. MORE
A group of statisticians who had argued for rejection were overruled, internal memos show, as high-ranking agency officials got behind an accelerated clearance for Biogen's drug MORE
Alzheimer's Disease Drugs (Pharmaceuticals) Clinical Trials Elderly Memory Brain Aducanumab (drug) Biogen Inc Food and Drug Administration Alzheimer's Assn your-feed-science your-feed-healthcare MORE
SUMMARY: DTC marketing is not the reason why prescription drugs cost so much. They research the drug online and ask their physician about it if they decide it’s a treatment option. 2wo: DTC marketing is one of the reasons prescription drugs cost so much. MORE
Initial results from a mid-stage study indicate the antiviral drug, molnupiravir, is safe. But whether it's hitting the study's main goal remains unclear MORE
SUMMARY: Americans spend twice as much per capita on drugs as residents of other wealthy nations, because ours is the only country that lets drugmakers set any price they want for their products. Via Axios “The 10 highest-selling drugs in the U.S. in the news Price of Rx drugs MORE
Unlike J&J's drug, however, Takeda's is given orally Exkivity follows Johnson & Johnson's Rybrevant on the market for treating lung tumors harboring specific mutations in the EGFR gene. MORE
This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials. MORE
Results from a mid-stage study showed Amgen's drug, sotorasib, shrank tumors in over a third of lung cancer patients, affirming earlier findings MORE
SUMMARY: Democratic lawmakers are weighing whether to include drug pricing measures that could extract tens of billions of dollars from the industry. We’re just not sure when,” said one drug industry lobbying source. The drug industry has had a large target on its back for a long time. MORE
SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. ” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science? MORE
Another TED talk on the evils of prescription drug marketing was filled with misinformation as usual. The disconnect between consumers and prescription drug marketing has grown quite a bit. The post Prescription drug marketing misconceptions appeared first on World of DTC Marketing.com. MORE
The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year MORE
The offering is the latest step in the rapid emergence of Adagio, which raised nearly $400 million and brought a drug to pivotal testing in less than a year MORE
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices MORE
QUICK READ: A two-month analysis of social media and prescription drugs found the number one reason online health seekers use social media is to share and ask questions about medication side effects. The post <strong>Social media and prescription drugs:</strong> A study. MORE
The Camargo Blog is publishing a four-part blog series highlighting those designation programs available specifically for products with rare disease indications: Orphan Drug Designation (ODD), Rare Pediatric Disease Designation (RPDD), and Humanitarian Use Device (HUD) designation. MORE
Register for our OTC-focused webinars to get a deeper look at five OTC drug monographs MORE
Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019 MORE
The agency’s acting head said a federal review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. Aduhelm (Drug) Alzheimer's Disease Drugs (Pharmaceuticals) Inspectors General Biogen Inc Food and Drug Administration Woodcock, Janet MORE
QUICK READ : Prescribers are reviewing some of their favorite prescribed drugs and are open to learning about new drugs in terms of efficacy and patient outcomes but you had better be ready to talk about patients beyond the science. MORE
AstraZeneca aims to help the biotech make a drug based on its findings After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight. MORE
Sunovion will receive $270 million from Otsuka, and as much as $620 million more, in exchange for splitting rights to four experimental psychiatric drugs MORE
A disappointing recommendation from outside data reviewers raises doubts about the DNA-targeting drug's benefits and puts pressure on Roche's partner, Ionis Pharmaceuticals MORE
s approval of the Alzheimer's drug aducanumab is inexplicable. . Drugs (Pharmaceuticals) Aduhelm (Drug) Alzheimer's Disease Food and Drug Administration Biogen IncThe F.D.A.'s MORE
This includes about one in five who report that they have not filled a prescription or took an over-the counter drug instead, and about one in ten who say they have cut pills in half or skipped a dose. Drug prices in the United States are extreme. Drug Prices MORE
Bintrafusp alfa was highlighted by GSK as a potential blockbuster drug as recently as January. Negative findings in two trials, however, led the companies to unwind their research collaboration MORE
Days after Aduhelm's approval, Biogen said an experimental drug that works in a different way didn't help patients, leading the company to stop research MORE
In a landmark study, fewer people given Ebanga died from Ebola virus infection than did those who received a control drug. Results from the trial also led to an OK for Regeneron's drug Inmazeb MORE
Aduhelm (Drug) Alzheimer's Disease Food and Drug Administration Drugs (Pharmaceuticals) Labeling and Labels (Product) Clinical Trials Elderly Science and Technology Regulation and Deregulation of Industry Research Brain Biogen Inc your-feed-science your-feed-healthcare MORE
Drugs (Pharmaceuticals) Sedatives Narcolepsy Sleep Food and Drug Administration Jazz Pharmaceuticals Inc Drug Abuse and TrafficJazz Pharmaceuticals brought in more than $1.7 billion last year selling GHB to narcolepsy patients. With the new approval, sales could soar. MORE
For an increasingly important set of drugs, Medicare has been driving up prices. Drugs (Pharmaceuticals) Health Insurance and Managed Care Prices (Fares, Fees and Rates) Medicare Elderly Biogen Inc Food and Drug Administration Aduhelm (Drug) Alzheimer's Disease MORE
Lumakras is the first drug proven effective For decades, scientists have tried unsuccessfully to target the KRAS gene, which is often mutated in lung, colon and pancreatic cancers. MORE
After several setbacks, most notably the failure of a brain cancer vaccine, Celldex has a chance at reinvention should early drug results pan out for the 16-year-old biotech MORE
A topical cream formulation of the drug in Incyte's top-selling product could help the company expand. The black box warning, though, might limit use MORE
Yet the media has led with “diabetes drug leads to major weight loss” Will doctors inform patients? The drug carries a potential risk for a type of thyroid tumor and has a boxed warning. This drug can be effective if patients follow the directions for weight loss. MORE
While it’s true, the drug industry developed COVID vaccines; the government spent billions on research pre-pandemic and $18 billion more on trials, production, and purchase. Drug corps are reaping record profits. Drug companies should prepare for this scenario. MORE
Approval of Aduhelm sets a precedent that could enable some drugs, like Eli Lilly's drug donanemab, to advance quickly and cause other previously sidelined ones to get a second look MORE
SUMMARY: The FDA has many puzzled as to why they approve some drugs with questionable data and ask for more data on other drugs. The FDA approves drugs on the potential to save a life, the cost of the drugs is never considered in the process. MORE
The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena MORE
Open source drug discovery was proposed in the past in connection with third-world diseases like tuberculosis and malaria, but it is in the context of first-world indications where it is needed most. The post Open Source “Wikipedia” for Drug Discovery appeared first on Pharma Mirror Magazine. MORE
The rejection of the new Alzheimer’s drug by the two major medical centers is one of the starkest signs of concern over its approval by the F.D.A. MORE
According to the KFF poll “ most adults – across partisans – don’t believe high drug prices are needed for drug companies to invest in new research instead agreeing that “even if U.S. The post Pharma losing the battle over drug prices. MORE
The expanded clearance in heart failure with reduced ejection fraction is expected to boost sales of the drug, called Jardiance MORE
Drugs Related Topics World of DTC Marketing
OCTOBER 12, 2021
According to the KFF poll “ most adults – across partisans – don’t believe high drug prices are needed for drug companies to invest in new research instead agreeing that “even if U.S. The post Pharma losing the battle over drug prices.
World of DTC Marketing
SEPTEMBER 7, 2021
While it’s true, the drug industry developed COVID vaccines; the government spent billions on research pre-pandemic and $18 billion more on trials, production, and purchase. Drug corps are reaping record profits. Drug companies should prepare for this scenario.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JULY 13, 2021
SUMMARY: The FDA has many puzzled as to why they approve some drugs with questionable data and ask for more data on other drugs. The FDA approves drugs on the potential to save a life, the cost of the drugs is never considered in the process.
World of DTC Marketing
AUGUST 27, 2021
The FDA approved 309 new drugs between 2011 and 2018, 38 per year on average. In 2018, the FDA approved 59 new drugs – an all-time high. The industry loses an average of $40 billion per year on drug development, part of which is due to trial delays.
Pharma Mirror
OCTOBER 4, 2021
Open source drug discovery was proposed in the past in connection with third-world diseases like tuberculosis and malaria, but it is in the context of first-world indications where it is needed most. The post Open Source “Wikipedia” for Drug Discovery appeared first on Pharma Mirror Magazine.
World of DTC Marketing
JUNE 16, 2021
This includes about one in five who report that they have not filled a prescription or took an over-the counter drug instead, and about one in ten who say they have cut pills in half or skipped a dose. Drug prices in the United States are extreme. Drug Prices
World of DTC Marketing
DECEMBER 10, 2020
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices
Bio Pharma Dive
SEPTEMBER 21, 2021
Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019
World of DTC Marketing
OCTOBER 6, 2020
This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials.
World of DTC Marketing
JUNE 27, 2021
Yet the media has led with “diabetes drug leads to major weight loss” Will doctors inform patients? The drug carries a potential risk for a type of thyroid tumor and has a boxed warning. This drug can be effective if patients follow the directions for weight loss.
Bio Pharma Dive
SEPTEMBER 22, 2021
A topical cream formulation of the drug in Incyte's top-selling product could help the company expand. The black box warning, though, might limit use
Bio Pharma Dive
AUGUST 23, 2021
The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year
Bio Pharma Dive
SEPTEMBER 30, 2021
Sunovion will receive $270 million from Otsuka, and as much as $620 million more, in exchange for splitting rights to four experimental psychiatric drugs
World of DTC Marketing
JUNE 1, 2021
SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. ” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science?
Bio Pharma Dive
JUNE 24, 2021
The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena
Bio Pharma Dive
MAY 28, 2021
Lumakras is the first drug proven effective For decades, scientists have tried unsuccessfully to target the KRAS gene, which is often mutated in lung, colon and pancreatic cancers.
Bio Pharma Dive
AUGUST 19, 2021
The expanded clearance in heart failure with reduced ejection fraction is expected to boost sales of the drug, called Jardiance
Bio Pharma Dive
SEPTEMBER 16, 2021
Unlike J&J's drug, however, Takeda's is given orally Exkivity follows Johnson & Johnson's Rybrevant on the market for treating lung tumors harboring specific mutations in the EGFR gene.
NY Times
AUGUST 20, 2021
For an increasingly important set of drugs, Medicare has been driving up prices. Drugs (Pharmaceuticals) Health Insurance and Managed Care Prices (Fares, Fees and Rates) Medicare Elderly Biogen Inc Food and Drug Administration Aduhelm (Drug) Alzheimer's Disease
World of DTC Marketing
JULY 21, 2021
SUMMARY: DTC marketing is not the reason why prescription drugs cost so much. They research the drug online and ask their physician about it if they decide it’s a treatment option. 2wo: DTC marketing is one of the reasons prescription drugs cost so much.
World of DTC Marketing
APRIL 9, 2021
QUICK READ: A two-month analysis of social media and prescription drugs found the number one reason online health seekers use social media is to share and ask questions about medication side effects. The post <strong>Social media and prescription drugs:</strong> A study.
Bio Pharma Dive
JULY 27, 2021
AstraZeneca aims to help the biotech make a drug based on its findings After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight.
NY Times
JULY 14, 2021
The rejection of the new Alzheimer’s drug by the two major medical centers is one of the starkest signs of concern over its approval by the F.D.A.
Bio Pharma Dive
SEPTEMBER 7, 2021
Register for our OTC-focused webinars to get a deeper look at five OTC drug monographs
Bio Pharma Dive
JUNE 22, 2021
A group of statisticians who had argued for rejection were overruled, internal memos show, as high-ranking agency officials got behind an accelerated clearance for Biogen's drug
World of DTC Marketing
DECEMBER 3, 2020
Another TED talk on the evils of prescription drug marketing was filled with misinformation as usual. The disconnect between consumers and prescription drug marketing has grown quite a bit. The post Prescription drug marketing misconceptions appeared first on World of DTC Marketing.com.
Bio Pharma Dive
MARCH 23, 2021
A disappointing recommendation from outside data reviewers raises doubts about the DNA-targeting drug's benefits and puts pressure on Roche's partner, Ionis Pharmaceuticals
Bio Pharma Dive
DECEMBER 22, 2020
In a landmark study, fewer people given Ebanga died from Ebola virus infection than did those who received a control drug. Results from the trial also led to an OK for Regeneron's drug Inmazeb
World of DTC Marketing
JULY 23, 2020
QUICK READ : Prescribers are reviewing some of their favorite prescribed drugs and are open to learning about new drugs in terms of efficacy and patient outcomes but you had better be ready to talk about patients beyond the science.
World of DTC Marketing
OCTOBER 5, 2021
SUMMARY: Americans spend twice as much per capita on drugs as residents of other wealthy nations, because ours is the only country that lets drugmakers set any price they want for their products. Via Axios “The 10 highest-selling drugs in the U.S. in the news Price of Rx drugs
Bio Pharma Dive
JULY 19, 2021
The offering is the latest step in the rapid emergence of Adagio, which raised nearly $400 million and brought a drug to pivotal testing in less than a year
NY Times
JULY 19, 2021
Aduhelm (Drug) Alzheimer's Disease Food and Drug Administration Drugs (Pharmaceuticals) Labeling and Labels (Product) Clinical Trials Elderly Science and Technology Regulation and Deregulation of Industry Research Brain Biogen Inc your-feed-science your-feed-healthcare
Bio Pharma Dive
JANUARY 28, 2021
Results from a mid-stage study showed Amgen's drug, sotorasib, shrank tumors in over a third of lung cancer patients, affirming earlier findings
NY Times
JUNE 15, 2021
s approval of the Alzheimer's drug aducanumab is inexplicable. . Drugs (Pharmaceuticals) Aduhelm (Drug) Alzheimer's Disease Food and Drug Administration Biogen IncThe F.D.A.'s
Bio Pharma Dive
JUNE 17, 2021
Days after Aduhelm's approval, Biogen said an experimental drug that works in a different way didn't help patients, leading the company to stop research
Bio Pharma Dive
OCTOBER 1, 2021
Bintrafusp alfa was highlighted by GSK as a potential blockbuster drug as recently as January. Negative findings in two trials, however, led the companies to unwind their research collaboration
Bio Pharma Dive
MARCH 8, 2021
Initial results from a mid-stage study indicate the antiviral drug, molnupiravir, is safe. But whether it's hitting the study's main goal remains unclear
Bio Pharma Dive
JUNE 9, 2021
Approval of Aduhelm sets a precedent that could enable some drugs, like Eli Lilly's drug donanemab, to advance quickly and cause other previously sidelined ones to get a second look
NY Times
JUNE 5, 2021
Alzheimer's Disease Drugs (Pharmaceuticals) Clinical Trials Elderly Memory Brain Aducanumab (drug) Biogen Inc Food and Drug Administration Alzheimer's Assn your-feed-science your-feed-healthcare
NY Times
AUGUST 12, 2021
Drugs (Pharmaceuticals) Sedatives Narcolepsy Sleep Food and Drug Administration Jazz Pharmaceuticals Inc Drug Abuse and TrafficJazz Pharmaceuticals brought in more than $1.7 billion last year selling GHB to narcolepsy patients. With the new approval, sales could soar.
Camargo
FEBRUARY 16, 2021
The Camargo Blog is publishing a four-part blog series highlighting those designation programs available specifically for products with rare disease indications: Orphan Drug Designation (ODD), Rare Pediatric Disease Designation (RPDD), and Humanitarian Use Device (HUD) designation.
Bio Pharma Dive
JULY 9, 2021
After several setbacks, most notably the failure of a brain cancer vaccine, Celldex has a chance at reinvention should early drug results pan out for the 16-year-old biotech
NY Times
JULY 9, 2021
The agency’s acting head said a federal review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. Aduhelm (Drug) Alzheimer's Disease Drugs (Pharmaceuticals) Inspectors General Biogen Inc Food and Drug Administration Woodcock, Janet
161 
Let's personalize your content